GenSight Biologics Reports Cash Position as of September 30, 2025

Core Insights - GenSight Biologics is a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders [1] Financial Summary - As of September 30, 2025, GenSight Biologics reported a cash and cash equivalents total of €0.6 million [1]